Table 1.
Baseline demographics and clinical characteristics.
| Total, n | 27 |
|---|---|
| Age, mean ± SD, years | 48 ± 13 |
| Female sex, n | 23 |
| BMI | 27.1 (19.1–39.7) |
| Heart rate | 73.4 ± 12.9 |
| Systolic blood pressure | 112.2 ± 15.1 |
| Diastolic blood pressure | 74.1 ± 10.2 |
| Etiology of PAH, n | |
| Idiopathic | 20 |
| Connective tissue disease | 4 |
| HIV associated | 2 |
| Congenital heart disease associated | 1 |
| Time to diagnosis, years | 2–30 |
| WHO functional class | |
| I | 1 |
| II–III | 12 |
| III | 14 |
| Six min walk distance, meters (mean ± SD) | 402 ± 124 |
| Hemodynamics, | |
| Mean PAP (mmHg) | 51 (26–80) |
| CI (L/min/m2) | 2.2 (1.4–3,3) |
| PVR (Wood units) | 15.2 (3.8–23) |
| PCWP (mmHg) | 11 (4–15) |
| Medications | |
| PDE inhibitors (Sildenafil), n | 23 |
| ERA, n | 8 |
| Inhaled prostacyclin, n | 3 |
| Warfarin, n | 11 |
| Diuretics, n | 10 |
BMI: Body mass index, PAP: Pulmonary artery pressure, CI: Cardiac index, PVR: Pulmonary vascular resistance, PCWP: Pulmonary capillary wedge pressure, PDE Phosphodiesterase, ERA Endothelin receptor agonists.